此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

使用合生元配方缓解乳腺癌患者脱发

2026年9月15日 更新者:GenieBiome Limited

关于合生元配方 (BLHK03) 缓解乳腺癌患者化疗引起的脱发 (CIA) 功效的双盲、随机、安慰剂对照试验

This study aims to explore the efficacy and safety of a synbiotic formula (BLHK03) in alleviating chemotherapy-induced alopecia (CIA) in breast cancer patients and the compositional and functional changes in the gut microbiome of breast cancer patients undergoing chemotherapy and treatment with BLHK03.

研究概览

详细说明

In a mice study, it was shown that oral administration of a probiotic isolated from healthy faeces, B. longum HK003, has protective effects against alopecia related to chemotherapy. Mice were treated with 100 mg/kg cyclophosphamide (CYP) once monthly, for 4 months. The CYP-treated mice were then treated with B. longum HK003 for 14 days. Results showed that B. longum treatment significantly enhanced skin thickness histologically. In the subcutis, the quantity and size of anagen follicles were increased, whilst the quantity of atrophic follicles were decreased.

Currently, there is no documentation of potential probiotic-drug interactions in breast cancer patients undergoing chemotherapy. A previous randomized controlled trial reported no adverse event associated with the use of synbiotics in breast cancer patients during the treatment period(9). Beneficial effects on chemotherapy-induced fatigue and abnormal stool consistency were also observed in subjects receiving synbiotics(9).

Biotin is a water-soluble vitamin that is naturally present in some food and available as a dietary supplement for healthy hair and nails due to its role in keratin production. Most healthy individuals achieve adequate intake of biotin through a well-balanced diet. Current recommendation for biotin by the Food and Nutrition Board (FNB) at the National Academies of Sciences, Engineering, and Medicine stated that the daily adequate intake (AI) for adults is 30 mcg/day. Although biotin has been widely used as dietary supplement, data on the actual benefit of its effect on hair growth is limited(10).

The use of B. longum HK003 in alleviating chemotherapy-induced alopecia in breast cancer patients has not been explored. This pilot, double-blind, randomised, placebo-controlled trial aims to explore on the efficacy and safety of a synbiotic formula (BLHK03) in alleviating chemotherapy-induced alopecia (CIA) in breast cancer patients.

研究类型

介入性

注册 (实际的)

7

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Hong Kong、香港
        • GenieBiome Limited
      • Hong Kong、香港
        • Heal Medical

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Females aged between 18 and 60 years who are newly diagnosed with stage I, II or III breast cancer
  • Planned chemotherapy including an anthracycline or taxane to be completed within 6 months
  • Mentally capable to participate in the study and provide informed consent

Exclusion Criteria:

  • Pre-existing female-pattern baldness resembling picture I-3 or higher on the Savin scale at baseline
  • History of hair transplantation, psoriasis or severe scalp infection
  • Undergoing or plan to receive scalp cooling
  • Plan for immunotherapy
  • Known pregnancy or lactating
  • Severe cardiac, hepatic, renal, pulmonary and haematic lesions or other life-threatening conditions
  • Use of antibiotics, probiotics or prebiotics one month prior to enrolment
  • No other alternative or complementary treatment for the cancer condition that may affect the gut microbiome analysis
  • History of allergy to probiotics or lactose
  • History of chemotherapy for other conditions

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
有源比较器:Active arm

Subjects will receive 1 sachet of BLHK03 daily from the start of the chemotherapy cycle to 2 months after the final dose of chemotherapy.

BLHK03 consists of a blend of probiotics (20 billion CFU in 1 sachet) and prebiotic compounds

安慰剂比较:Placebo arm

Subjects will receive 1 sachet of active placebo daily from the start of the chemotherapy cycle to 2 months after the final dose of chemotherapy.

Active placebo contains 5mcg of Vitamin B7

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The proportion of subjects with a score of ≤ 2 on the Dean scale (corresponding to hair loss ≤ 50%) 2 months after the final dose of chemotherapy
大体时间:Baseline to 2 months after the final dose of chemotherapy

The change of Dean scale (corresponding to hair loss) after chemotherapy compared to baseline. Score 0 means no hair loss and score 4 means all hair is fallen down.

Baseline to 2 months after the final dose of chemotherapy

次要结果测量

结果测量
措施说明
大体时间
Gut microbial change at 2 months after the final dose of chemotherapy
大体时间:Baseline to 2 months after the final dose of chemotherapy

The change of gut microbiota composition at 2 months after the final dose of chemotherapy compared to baseline

Baseline to 2 months after the final dose of chemotherapy
Adverse event rates related to the study during the study period
大体时间:Baseline to 2 months after the final dose of chemotherapy

The adverse events reported throughout the study

Baseline to 2 months after the final dose of chemotherapy

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Jessica Ching, PhD、GenieBiome Limited

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年9月11日

初级完成 (实际的)

2025年8月18日

研究完成 (实际的)

2025年8月18日

研究注册日期

首次提交

2024年8月15日

首先提交符合 QC 标准的

2024年8月15日

首次发布 (实际的)

2024年8月19日

研究记录更新

最后更新发布 (实际的)

2026年9月18日

上次提交的符合 QC 标准的更新

2026年9月15日

最后验证

2025年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅